Patents Examined by Brian J. Gangle
  • Hyposialylation disorders
    Patent number: 9341619
    Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 17, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Emory University
    Inventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
  • Stable formulations for parenteral injection of peptide drugs
    Patent number: 9339545
    Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: May 17, 2016
    Assignee: Xeris Pharmaceuticals, Inc.
    Inventors: Steven Prestrelski, John Kinzell
  • Vaccine against streptococcal infections based on recombinant proteins
    Patent number: 9333252
    Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: May 10, 2016
    Assignee: Intervacc AB
    Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
  • Vaccine for protection against disease
    Patent number: 9333251
    Abstract: Compositions and methods for protecting a susceptible host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: May 10, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dennis J. Kopecko, De-Qi Xu, John O. Cisar
  • Chemokine receptor binding polypeptides
    Patent number: 9328174
    Abstract: The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 3, 2016
    Assignee: Novartis AG
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from as next generation plague vaccines
    Patent number: 9328149
    Abstract: Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal ?-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the ?-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 3, 2016
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Pan Tao
  • Antibodies directed against IL-17
    Patent number: 9328166
    Abstract: The invention relates to an isolated interleukin-17 (IL-17)-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 78, or SEQ ID NO: 79, and an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The invention also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: May 3, 2016
    Assignee: AnaptysBio, Inc.
    Inventors: Robert Horlick, David King, Peter Bowers, Jennifer Dalton, Betty Wu, Traci Roberts, Xue Zhang, Laurence Altobell, III
  • Methods and compositions for cytomegalovirus IL-10 protein
    Patent number: 9321813
    Abstract: The present invention provides methods and compositions for treating and/or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus interleukin-10 (IL-10) protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: April 26, 2016
    Assignees: UAB Research Foundation, The Regents of the University of California
    Inventors: Mark R. Walter, Peter A. Barry
  • Pharmaceutical compositions containing toxoids A and B
    Patent number: 9320790
    Abstract: This invention relates to compositions including Clostridium difficile toxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: April 26, 2016
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: C. Russell Middaugh, Richard Fahrner, Peter Ciarametaro
  • Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
    Patent number: 9320719
    Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: April 26, 2016
    Assignee: Northwestern University
    Inventors: Phillip B. Messersmith, Kvar C. L. Black, IV, Ji Yi, Jose G. Rivera
  • Treatment methods using atoxic neurotoxin derivatives
    Patent number: 9315549
    Abstract: The present invention relates to a treatment method. This method involves contacting a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin. Contacting is carried out to treat the subject. The derivative of a Clostridial neurotoxin does not possess a cargo attachment peptide sequence at its N-terminus.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: April 19, 2016
    Assignee: New York University
    Inventors: Edwin J. Vazquez-Cintron, Konstantin Ichtchenko, Philip A. Band
  • Metabolically enhanced cyanobacterium with sequentially inducible production genes for the production of a first chemical compound
    Patent number: 9315820
    Abstract: This invention provides a metabolically enhanced cyanobacterium for the production of a chemical compound of interest, having at least two first production genes encoding first biocatalysts for the production of the first chemical compound. One of the two first production genes is under the transcriptional control of a first promoter for the first production gene, whereas the other of the two first production genes is under the transcriptional control of a second promoter for the first production gene. The first promoter and second promoter are separately inducible under different conditions and the at least two first biocatalysts catalyze the same chemical reaction. Metabolically enhanced cyanobacteria according to the present invention allow prolonged production of first chemical compounds.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: April 19, 2016
    Assignee: Algenol Biotech LLC
    Inventors: Ulf Dühring, Alexandra Friedrich, Kerstin Baier, Heike Enke, Dan Kramer
  • Compositions and methods for detecting, treating, and protecting against fusobacterium infection
    Patent number: 9308247
    Abstract: The present invention relates to protecting against, treating, and detecting Fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kDa Adhesin protein are provided to protect against, treat, and detect Fusobacteria infections in a subject. In one aspect, vaccines capable of inducing an immune response to a 40 kDa Adhesin protein are used to protect against Fusobacteria infection. Also, nucleic acid molecules, proteins, immunogens, antibodies, and antisense molecules derived from the sequences of the 40 kDa Adhesin protein may be used to protect against, treat, and detect Fusobacteria infections in a subject.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: April 12, 2016
    Assignee: Kansas State University Research Foundation
    Inventors: Sanjeev Narayanan, Amit Kumar, Tiruvoor Nagaraja, Muckatira Chengappa
  • Food supplement having high immunological value, based on a protein matrix
    Patent number: 9308241
    Abstract: The invention relates to a food supplement having high immunological value, based on a protein matrix, i.e. a food compound with high immunological value, based on the mixture of four protein sources: i. biotechnologically improved bovine colostrum; ii. egg albumin; iii. soy protein isolate; and, iv. concentrated whey protein.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 12, 2016
    Inventor: Miguel Alvaro Zuñiga Benavides
  • Arabinogalactan for enhancing the adaptive immune response
    Patent number: 9302000
    Abstract: The present invention discloses a composition containing Arabinogalactan for enhancing the adaptive immune response in subjects to foreign antigen(s) by administering said composition prior, during and after the phase of exposure to said foreign antigen(s). Furthermore, the present invention relates to a vaccination kit comprising a composition comprising Arabinogalactan and a vaccine.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: April 5, 2016
    Inventors: Bryan Rodriguez, Kevin Q. Owen, Ulla Freitas, Jay Udani
  • Stable formulations for parenteral injection of peptide drugs
    Patent number: 9302010
    Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: April 5, 2016
    Assignee: Xeris Pharmaceuticals, Inc.
    Inventors: Steven Prestrelski, John Kinzell
  • Anti-hDlk-1 antibody having an antitumor activity in vivo
    Patent number: 9303086
    Abstract: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: April 5, 2016
    Assignee: LIVTECH, INC.
    Inventors: Koji Nakamura, Hiroyuki Yanai, Toru Kanke, Naoya Tsurushita, Shankar Kumar
  • Stable formulations for parenteral injection of peptide drugs
    Patent number: 9295724
    Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: March 29, 2016
    Assignee: Xeris Pharmaceuticals, Inc.
    Inventors: Steven Prestrelski, John Kinzell
  • Chromatography ligand comprising domain C from protein A for antibody isolation
    Patent number: 9290549
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 22, 2016
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Stabilization and storage of biological pharmaceutical compositions
    Patent number: 9289381
    Abstract: The present invention relates to compositions and methods for the preparation, stabilization, and/or storage of active agents, particularly therapeutic proteins and polypeptides such as Interleukin-2.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: March 22, 2016
    Assignees: The University of North Carolina at Charlotte, The Charlotte-Mecklenburg Hospital Authority, Monash University
    Inventors: Gloria Elliott, Douglas MacFarlane, David M. Foureau, Iain McKillop